Skye Bioscience Appoints New CMO, Elects Director
Ticker: SKYE · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1516551
Sentiment: neutral
Topics: leadership-change, board-election, executive-appointment
TL;DR
Skye Bioscience beefs up leadership with a new CMO and board member.
AI Summary
Skye Bioscience, Inc. announced on February 29, 2024, the appointment of Dr. Michael J. McVicar as Chief Medical Officer and the election of Dr. Robert L. T. Smith to its Board of Directors. The company also reported on its compensatory arrangements for certain officers. This filing follows previous name changes from Emerald Bioscience, Inc. and Nemus Bioscience, Inc.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts and bring new expertise to the company's leadership, potentially impacting its drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key leadership roles and board composition can introduce uncertainty or signal strategic shifts that may affect the company's future performance.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- Dr. Michael J. McVicar (person) — Appointed Chief Medical Officer
- Dr. Robert L. T. Smith (person) — Elected to Board of Directors
- Emerald Bioscience, Inc. (company) — Former Company Name
- Nemus Bioscience, Inc. (company) — Former Company Name
FAQ
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 29, 2024.
What is Skye Bioscience, Inc.'s state of incorporation?
Skye Bioscience, Inc. is incorporated in Nevada.
Who has been appointed as the new Chief Medical Officer?
Dr. Michael J. McVicar has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Dr. Robert L. T. Smith has been elected to the Board of Directors.
What were some of Skye Bioscience's former company names?
Skye Bioscience, Inc. was formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc.
Filing Stats: 789 words · 3 min read · ~3 pages · Grade level 9.7 · Accepted 2024-03-04 16:23:48
Key Financial Figures
- $40,000 — will receive an annual cash retainer of $40,000 for service on the Board and an additio
- $2,500 — rd and an additional annual retainer of $2,500 for service as a member of the Nominati
- $3,500 — e Governance Committee of the Board and $3,500 for service as a member of the Compensa
Filing Documents
- skye-20240229.htm (8-K) — 32KB
- a240304_skyejenkinsboard.htm (EX-99.1) — 12KB
- 0001516551-24-000034.txt ( ) — 163KB
- skye-20240229.xsd (EX-101.SCH) — 2KB
- skye-20240229_lab.xml (EX-101.LAB) — 22KB
- skye-20240229_pre.xml (EX-101.PRE) — 11KB
- skye-20240229_htm.xml (XML) — 2KB
01 Other Events
Item 8.01 Other Events. On March 4, 2024, the Company issued a press release announcing the election of Dr. Jenkins as a director. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SKYE BIOSCIENCE, INC. Dated: March 4, 2024 /s/ Punit Dhillon Name: Punit Dhillon Title: Chief Executive Officer